Alfred L. Garfall, MD, MS, discusses the potential of CAR T-cell therapy in multiple myeloma.
Alfred L. Garfall, MD, MS, assistant professor of medicine, the Hospital of the University of Pennsylvania, discusses the potential of CAR T-cell therapy in multiple myeloma.
CAR T-cell therapy has shown high response rates in heavily pretreated and high-risk patients multiple myeloma, says Garfall.
The modality has been shown to lead to extended treatment-free remissions. Although the majority of patients with multiple myeloma who receive CAR T-cell therapy will relapse, the modality has shown potential for long-term immune surveillance against relapse, concludes Garfall.